# US 12,595,510 B2 · Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,595,510 B2 - Document ID: US12595510B2 - Status: Granted - Kind: B2 - Application number: 17/292,926 - Filed: 2019-11-14 - Published: 2022-01-06 - Granted: 2026-04-07 - Earliest claimed: 2018-11-15 - Assignees: Janssen Biotech, Inc. - Applicants: Janssen Biotech, Inc. - Inventors: Frederic Baribaud; Carrie Brodmerkel; Xilin Li; Takahiro Sato; Shannon Telesco; Feifei Yang; Prerak Desai - Web page: https://patentgrep.com/patent/US12595510B2 ## CPC - C12Q 1/6883: for diseases caused by alterations of genetic material - G01N 33/6893: {related to diseases not provided for elsewhere} - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/158: Expression markers - G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease. ## Claims ### Claim 1 A method of treating a subject diagnosed with an inflammatory bowel disease (IBD), comprising: (i) identifying a subject diagnosed with an IBD to be a responder to an IBD treatment comprising an anti-interleukin 23 (anti-IL23) antibody, the method comprising: a). contacting a sample from a subject with a set of probes capable of detecting a panel of biomarkers comprising 13 biomarkers selected from the group consisting of CKLF-like MARVEL transmembrane domain containing 2 (CMTM2), complement C5a receptor 1 (C5AR1), fibroblast growth factor 2 (FGF2), glycerol kinase (GK), hepatocyte growth factor (HGF), interleukin 1 receptor antagonist (IL1RN), leukocyte immunoglobulin like receptor A2 (LILRA2), nicotinamide phosphoribosyltransferase (NAMPT), pappalysin 1 (PAPPA), synuclein alpha (SNCA), superoxide dismutase 2, mitochondrial (SOD2), STEAP4 metalloreductase (STEAP4), and zinc finger BED-type containing 3 (ZBED3); b). determining a signature score of the panel of biomarkers, wherein the determining comprises determining the baseline gene expression levels of the panel of biomarkers; and c). identifying a subject to be a responder to the IBD treatment if the signature score of the panel of biomarkers is above a pre-specified threshold indicative of response; and (ii) administering to the subject who has been identified as a responder in c) a therapeutically effective amount of the IBD treatment. ### Claim 2 (depends on 1) The method of claim 1, wherein a. the sample is obtained before the subject is treated with the IBD treatment; or b. the probe is selected from the group consisting of an aptamer, an antibody, an affibody, a peptide, and a nucleic acid. ### Claim 3 (depends on 2) The method of claim 2, wherein the probe is a nucleic acid. ### Claim 4 (depends on 2) The method of claim 2, wherein the probe is selected from the group consisting of SEQ ID NOS. 1-14, SEQ ID NO. 17, SEQ ID NO. 20, SEQ ID NO. 23, SEQ ID NO. 26, SEQ ID NO. 29, SEQ ID NO. 32, SEQ ID NO. 35, SEQ ID NO. 38, SEQ ID NO. 41, SEQ ID NO. 44, SEQ ID NO. 47, and SEQ ID NO. 50. ### Claim 5 (depends on 1) The method of claim 1, wherein the gene expression levels of the panel of biomarkers are determined by quantitative polymerase chain reaction (qPCR). ### Claim 6 (depends on 5) The method of claim 5, wherein the qPCR primers are selected from the group consisting of SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 25, SEQ ID NO. 27, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 40, SEQ ID NO. 42, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 46, SEQ ID NO. 48, SEQ ID NO. 49, SEQ ID NO. 51, and SEQ ID NO. 52. ### Claim 7 (depends on 1) The method of claim 1, wherein the pre-specified threshold level is a. selected from the group consisting of between-3.9000 and 1.1000; b. −3.8234; or c. 1.0000. ### Claim 8 (depends on 1) The method of claim 1, further comprising predicting the response by one or more other characteristics of the subject. ### Claim 9 (depends on 8) The method of claim 8, wherein the other characteristics are selected from the group consisting of protein levels, gut microbiome, histology and clinical characteristics of the subject. ### Claim 10 (depends on 1) The method of claim 1, further comprising measuring the response at or after week 6, 30 or 50 of the IBD treatment, or anytime in between. ### Claim 11 (depends on 1) The method of claim 1, wherein the sample is a tissue sample or a blood sample. ### Claim 12 (depends on 1) The method of claim 1, wherein the IBD is at least one of ulcerative colitis (UC) or Crohn's disease (CD). ### Claim 13 (depends on 1) The method of claim 1, wherein the subject had previously failed or were intolerant of at least one therapy selected from the group consisting of: vedolizumab, corticosteroids, azathioprine (AZA), and 6 mercaptopurine (6 MP), or the subject had demonstrated corticosteroid dependence. ### Claim 14 (depends on 1) The method of claim 1, wherein the anti-IL23 antibody is ustekinumab.